Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Phase Distribution

Ph phase_4

60%

Ph not_applicable

20%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

1(20.0%)

Phase 4Post-market surveillance

3(60.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (20.0%)

Phase 43 (60.0%)

N/A1 (20.0%)

Trials by Status

completed480%

withdrawn120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_4

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

NCT03387462

completedphase_4

The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community

NCT03120936

Clinical Trials (5)

Showing 5 of 5 trials

NCT03771638Phase 4

DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men

Completed

NCT05458765Phase 2

Project Engage: Oral PrEP Acceptability

Completed

NCT04329442Not Applicable

Accelerated PrEP Access for Black MSM and TW

Withdrawn

NCT03387462Phase 4

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

Completed

NCT03120936Phase 4

The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5